Your Expert Speakers

Speakers

Expand/Collapse

Andrew Weinberg
President & Chief Scientific Officer
AgonOx

Day One

Tuesday 25th October 2022

8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL

Day Two

Wednesday 26th October 2022

2:00 pm | Are Tumor-Reactive TIL Really Exhausted or Can They Be Rescued For Adoptive T cell Therapy: Clinical Implications

Daniel Powell
Assocaite Professor of Pathology & Laboratory Medicine
University of Pennsylvania

Day One

Tuesday 25th October 2022

12:00 pm | Methods for Enrichment of TIL with Autologous Tumor-Reactivity & Stem-Like Qualities

8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL

Eduardo Davila
Professor & Director of Immunotherapy Medical Oncology
University of Colorado Comprehensive Cancer Center

Pre-Conference Day

Monday 24th October 2022

3:00 pm | Workshop C - Optimizing Cryopreservation to Support the Development of TIL Therapies

Friedrich Graf Finckenstein
Chief Medical Officer
Iovance Biotherapeutics

Day One

Tuesday 25th October 2022

8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL

Ian Hardy
R&D Reagents
Miltenyi Biotec

Day One

Tuesday 25th October 2022

10:00 am | CliniMACS Prodigy TRT System: Streamlining TIL Manufacturing

Jan Meulen
Chief Scientific Officer
Obsidian Therapeutics

Day Two

Wednesday 26th October 2022

1:00 pm | Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15

Karrie Wong
Director of Cell Therapy
KSQ Therapeutics, Inc

Pre-Conference Day

Monday 24th October 2022

9:00 am | Workshop A - Developing an Analytical Genotoxicity Package: From Preclinical Development Through Drug Product Release & Beyond

Kumar Karyampudi
Director Cell Therapy Facility
Moffitt Cancer Center

Day Two

Wednesday 26th October 2022

9:00 am | Defining Critical Quality Attributes (CQAs) of TIL Products

Mark Dudley
Chief Scientific Officer
Instil Bio

Day One

Tuesday 25th October 2022

11:30 am | Developing a Novel Costimulatory Antigen Receptor With Dual CD28/ CD40 Signaling Domains to Improve Adoptive Cell Therapies

8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL

Micah Benson
Senior Vice President
KSQ Therapeautics

Day Two

Wednesday 26th October 2022

12:00 pm | Rational Design of CRISPR/Cas9-engineered TIL Therapies

Michael Lotze
Chief Cell Therapy Officer
Nurix Therapeutics

Day One

Tuesday 25th October 2022

1:30 pm | Combining TIL with Small Molecule Inhibitors to Enhance T – Cell Expansion & Phenotypes

8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL

Moran Meiron
Director of Advanced Therapies
Orgenesis Inc.

Day Two

Wednesday 26th October 2022

9:30 am | Decentralized Approach to Autologous Cell Therapy Manufacturing – Advantages of Harmonized TILs Manufacturing at a Point of Care

Nicholas Restifo
Stealth Explorer
Immunotherapy

Day One

Tuesday 25th October 2022

9:30 am | Enhancing Stemness of Polyclonal T Cells to Improve Anti-Tumor Activity

Peter Prieto
Assistant Professor
University of Rochester

Day One

Tuesday 25th October 2022

3:30 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies

Sergio Quezada
Chief Scientific Officer
Achilles Therapeutics Limited

Day Two

Wednesday 26th October 2022

10:00 am | Using AI-Powered Bioinformatics & Antigen Presenting Cells to Create a Measurable & Trackable Precision TIL Product Targeting Clonal Neoantigens

Simon Turcotte
Associate Professor of Surgery, T Cell Immunotherapy Program Lead
Université de Montréal

Day One

Tuesday 25th October 2022

3:30 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies

Pre-Conference Day

Monday 24th October 2022

12:00 pm | Workshop B - Cell Sorting to Manufacture TIL Products Enriched in Neoantigen-Reactive T Cells: What Are The Best Markers, Selection & Expansion Strategies?

Stephanie Woodall
Director - Head of Quality
KSQ Therapeautics

Pre-Conference Day

Monday 24th October 2022

9:00 am | Workshop A - Developing an Analytical Genotoxicity Package: From Preclinical Development Through Drug Product Release & Beyond

Sylvia Lee
Associate Professor, Program in Immunology Clinical Research Division
Fred Hutchinson Cancer Research Center (FHCRC)

Day One

Tuesday 25th October 2022

3:30 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies

Tom Henley
Chief Scientific Officer
Intima Bioscience

Day Two

Wednesday 26th October 2022

12:30 pm | Utilizing Multiplex CRISPR Gene Editing to Assess New Classes of Intra Cellular Immune Checkpoint Molecules for Application in TIL

Ulrik Cordes
Founder & Chief Executive Officer
Cbio

Day One

Tuesday 25th October 2022

2:00 pm | Next-Gen TIL Therapy With a Broader T-Cell Repertoire – The Key to Unlocking Less Immunogenic Solid Tumor Indications